Service de génétique médicale, Centre de référence des maladies mitochondriales, CHU Nice, Université Côte d'Azur, CNRS, INSERM, IRCAN, Nice, France.
Filnemus, laboratoire de génétique moléculaire, CHU, Montpellier, France.
Ann Clin Transl Neurol. 2024 Jun;11(6):1478-1491. doi: 10.1002/acn3.52062. Epub 2024 May 4.
The objective of this study was to evaluate the implementation of NGS within the French mitochondrial network, MitoDiag, from targeted gene panels to whole exome sequencing (WES) or whole genome sequencing (WGS) focusing on mitochondrial nuclear-encoded genes.
Over 2000 patients suspected of Primary Mitochondrial Diseases (PMD) were sequenced by either targeted gene panels, WES or WGS within MitoDiag. We described the clinical, biochemical, and molecular data of 397 genetically confirmed patients, comprising 294 children and 103 adults, carrying pathogenic or likely pathogenic variants in nuclear-encoded genes.
The cohort exhibited a large genetic heterogeneity, with the identification of 172 distinct genes and 253 novel variants. Among children, a notable prevalence of pathogenic variants in genes associated with oxidative phosphorylation (OXPHOS) functions and mitochondrial translation was observed. In adults, pathogenic variants were primarily identified in genes linked to mtDNA maintenance. Additionally, a substantial proportion of patients (54% (42/78) and 48% (13/27) in children and adults, respectively), undergoing WES or WGS testing displayed PMD mimics, representing pathologies that clinically resemble mitochondrial diseases.
We reported the largest French cohort of patients suspected of PMD with pathogenic variants in nuclear genes. We have emphasized the clinical complexity of PMD and the challenges associated with recognizing and distinguishing them from other pathologies, particularly neuromuscular disorders. We confirmed that WES/WGS, instead of panel approach, was more valuable to identify the genetic basis in patients with "possible" PMD and we provided a genetic testing flowchart to guide physicians in their diagnostic strategy.
本研究旨在评估法国线粒体网络 MitoDiag 中从靶向基因panel 到全外显子测序(WES)或全基因组测序(WGS)的 NGS 实施情况,重点关注线粒体核编码基因。
MitoDiag 对 2000 多名疑似原发性线粒体疾病(PMD)患者进行了靶向基因panel、WES 或 WGS 测序。我们描述了 397 名经基因证实的患者的临床、生化和分子数据,这些患者携带核编码基因中的致病性或可能致病性变异。
该队列表现出很大的遗传异质性,鉴定出 172 个不同的基因和 253 个新变异。在儿童中,发现与氧化磷酸化(OXPHOS)功能和线粒体翻译相关的基因中的致病性变异明显更为普遍。在成年人中,致病性变异主要发生在与 mtDNA 维持相关的基因中。此外,进行 WES 或 WGS 检测的患者中相当大一部分(儿童分别为 54%(42/78)和 48%(13/27),成年人分别为 54%(42/78)和 48%(13/27))显示出 PMD 模拟物,代表在临床上类似于线粒体疾病的病理学。
我们报告了法国最大的疑似 PMD 患者队列,这些患者携带核基因中的致病性变异。我们强调了 PMD 的临床复杂性,以及从其他病理学中识别和区分它们的挑战,特别是神经肌肉疾病。我们证实,与 panel 方法相比,WES/WGS 更有利于识别“可能”PMD 患者的遗传基础,并提供了一个基因检测流程图,以指导医生制定诊断策略。